Immuneering (IMRX)CHIEF SCIENTIFIC OFFICER bought ~$25K

~$25K

Approx. value · 6,035 sh @ $4.15

383K

Holds after · shares reported

Traded

Jun 15, 2026

Filed

Jun 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 15, 2026Company filing · Form 8-K · ResultsReported its results
2. Jun 11, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).”
3. Jun 15, 2026 · this disclosureInsider · Their largest buy since 2021Officer purchased ~$25K of IMRX shares in the open market

What came next

1. Jun 23, 2026InsiderCEO purchased ~$11K of IMRX shares in the open market
2. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Immuneering

OQRO holds no insider, Congress, fund or contract record for Immuneering dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMRX page.

Other recent filings by Brett Matthew Hall, CHIEF SCIENTIFIC OFFICER

• SEC Form 4 at Immuneering (IMRX)Jan 16, 2026
• SEC Form 4 at Immuneering (IMRX)Jun 24, 2025
• SEC Form 4 at Immuneering (IMRX)Jun 24, 2025

The full history of Brett Matthew Hall, CHIEF SCIENTIFIC OFFICER is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Immuneering

• SEC Form 4Jun 24, 2026
• SEC Form 4Jan 21, 2026
• SEC Form 4Jan 20, 2026
• SEC Form 4Jan 16, 2026
• SEC Form 4Jan 15, 2026
• SEC Form 4Jan 14, 2026

Everything OQRO holds on this company is on its IMRX page.